Cognition Therapeutics reports once-daily drug’s potential to slow Alzheimer’s progression, showing promise with favorable safety profile. Cognition Therapeutics, Inc. recently disclosed findings from their Phase 2 SHINE trial, investigating the efficacy of CT1812, an experimental oral treatment for Alzheimer’s disease. The study, which involved 153 adults with mild-to-moderate Alzheimer’s, assessed the cognitive and functional impacts of daily CT1812 doses over six months, and has reported approximately 40% less cognitive decline in patients administered CT1812 compared with those on a placebo. The SHINE trial, a double-blind, placebo-controlled study, explored two dosages of CT1812 (100mg and 300mg), with the primary objective being…
Author: Michael
Arnold Schwarzenegger has significantly boosted
According to registered dietitian and certified
In a recent study published in Read More
Longevity.
Curious about the potential risks and side effec
Herbal remedies have long been used to improve c
Recent study indicates that hyperbaric oxygen th
Recent research highlights a growing concern amo
In a recent revelation that captured public inte